



# SUMMARY OF ADNI Plasma INVENTORY

**ADNI UPENN BIOMARKER CORE**



1. Percentage of Subjects Providing Plasma per ADNI study phase
  - a. Figure 1 ..... [page 3](#)
  - b. Table 1 ..... [page 4](#)
  
2. Comparison of Originally Received Plasma Aliquots at BASELINE for all ADNI
  - a. Figure 2a (BASELINE) ..... [page 5](#)
  - b. Figure 2b (Yr 1 Follow-Up for ADNI 1) ..... [page 6](#)
  - c. Table 2ab ..... [page 7](#)
  
3. Comparison of Currently Available Plasma Aliquots at BASELINE for all ADNI
  - a. Figure 2c (BASELINE) ..... [page 8](#)
  - b. Figure 2d (Yr 1 Follow-Up for ADNI 1) ..... [page 9](#)
  - c. Table 2cd ..... [page 10](#)
  
4. Number of Originally Received Plasma Aliquots at BASELINE and Follow-Up Visit for ADNI 1
  - a. Figure 3a ..... [page 11](#)
  - b. Table 3a ..... [page 12](#)
  
5. Number of Currently Available Plasma Aliquots at BASELINE and Follow-Up Visits for ADNI 1
  - a. Figure 3b ..... [page 13](#)
  - b. Table 3b ..... [page 14](#)
  
6. Number of Originally Received Plasma Aliquots for ADNI 2 Phase at BASELINE and Follow-Up Visits
  - a. Figure 4a ..... [page 15](#)
  - b. Table 4a ..... [page 16](#)
  
7. Number of Currently Available Plasma Aliquots for ADNI 2 at BASELINE and Follow-Up Visits
  - a. Figure 4b ..... [page 17](#)
  - b. Table 4b ..... [page 18](#)
  
8. Summary of CSF, Plasma, Serum, Whole Blood Aliquots shipped out
  - a. Table/Figure 5 ..... [page 19](#)
  
9. Graph and Table of Summary of Plasma Aliquots used for Luminex runs
  - a. Figure 6 and Table 6 ..... [page 24](#)

**10. Percentage of Subjects Providing CSFs per ADNI study phase**

- a. Figure 7 ..... [page 26](#)
- b. Table 7 ..... [page 27](#)

**11. Number of Originally Received CSF Aliquots for ADNI DOD**

at BL and Yr 1 Follow-Up Visits

- a. Figure 8a ..... [page 28](#)
- b. Table 8a ..... [page 29](#)


**12. Number of Currently Available CSF Aliquots for ADNI DOD**

at BL and Yr 1 Follow-Up Visits

- a. Figure 9b ..... [page 30](#)
- b. Table 9b ..... [page 31](#)

*\* Note: BL = "Baseline"*

## Subjects Providing Plasma at Baseline in each ADNI Study Phase (Graph)



**Figure 1. Comparison by Percentage of subjects who provided plasma at Baseline for each ADNI Study Phase.** The figure above compares the percentage of those enrolled that provided plasma samples at Baseline between ADNI 1, ADNI GO, and ADNI 2. As of **January 5th, 2015**, approximately 99.51% of those enrolled in ADNI 1 provided plasma samples at baseline compared to 95.59% of those enrolled in ADNI GO and 96.13% of those enrolled in ADNI 2.

\* At least 96.13% (N = 771) of the 802 subjects enrolled in ADNI 2 have provided plasma samples at Baseline as of **January 5th, 2015**. This report also includes the number of aliquots from samples that were initially received thawed and therefore re-drawn at a later date.

[Table of Contents](#)

## Subjects Providing Plasma at Baseline in each ADNI Study Phase (Table)

### Summary Table of Percentage of subjects providing plasma samples within each ADNI Study Phase

ADNI Group	Baseline(De-Novo)			Year 1 Follow-Up(De Novo)	
	Number of Subjects enrolled as of <i>Jan. 5<sup>th</sup>, 2015</i>	Number who provided PLA	% who provided PLA per ADNI group	Number who provided PLA	% who provided PLA per ADNI group
ADNI 1	822	821	99.88%	721	87.77%
ADNI GO	136	†130	95.59%	8	5.88%
ADNI 2	802	‡771	96.13%	729	90.90%
<b>Total</b>	1760	1722	97.84%	1458	82.84%


**Table 1. Summary Table of Percentage of subjects providing plasma samples within each ADNI Study Phase at Baseline and at 1 year Follow-Up.** This is a summary table for Figure 1, detailing the number and percent of subjects providing plasma samples within each ADNI Study Phase, as well as the number and percentage of those who provided plasma samples at 1 year follow-up as of **Jan. 5th, 2015**. “De Novo” indicates that these are subjects who were initially enrolled in an ADNI study phase and followed up within that same study phase. This also includes the number of aliquots from samples that were initially received thawed and therefore re-drawn at a later date.

† As of 12/2011, a total of 130 out of the 136 subjects enrolled in ADNI GO have provided plasma samples at Baseline. Plasma samples at 1-year follow-up are completed.

‡ As of 1/2014, a total of 771 out of the 802 subjects enrolled in ADNI 2 have provided plasma samples at Baseline. By 1/2015, the final number of plasma samples at 1-year follow-up that have been collected will be known.

[Table of Contents](#)


## Originally Received Plasma at Baseline for all ADNI (Graph)



**Figure 2a. Comparison of Originally Received Plasma Aliquots at Baseline for ADNI 1, GO, and 2.** The graph above displays the frequency of originally received plasma aliquots and the number of subjects who have provided plasma samples at Baseline in ADNI 1, GO, and 2. The volume of each plasma aliquot is 0.5 ml. For example, 138 of the subjects enrolled in ADNI 1 originally provided between 6 to 10 plasma aliquots, compared to 12 subjects enrolled in ADNI GO and 44 subjects enrolled in ADNI 2.

[Table of Contents](#)

## Originally Received Plasma at 1-yr Follow-Up for all ADNI (Graph)



**Figure 2b. Number of Originally Received Plasma Aliquots at 1-Year Follow-Up for ADNI 1, GO, and 2.** The graph above displays the frequency of originally received plasma aliquots and number of subjects who have provided plasma samples at 1 year Follow-Up in ADNI 1, ADNI GO, and ADNI 2. The volume of each plasma aliquot is 0.5 ml. For example, 83 of the subjects enrolled in ADNI 1 have provided between 6 to 10 plasma aliquots, compared to 4 of the subjects initially enrolled in ADNI GO and 28 of the subjects initially enrolled in ADNI 2.

[Table of Contents](#)

## Summary Table of Originally Received Plasma aliquots for all ADNI

### Summary Table of Number of Subjects providing plasma samples within each ADNI Study Phase

Frequency of <i>Originally Received</i> Aliquots at BL and Yr 1 Follow-Up (De Novo)						
Number of Aliquots	ADNI 1		ADNI GO		ADNI 2	
	BL	Yr 1	BL	Yr 1	BL	Yr 1
0	0	0	0	0	0	0
1 to 5	42	33	4	0	6	4
6 to 10	138	83	12	4	44	28
11 to 15	444	317	43	1	171	168
16 to 20	194	284	59	3	477	457
21 to 25	3	4	12	0	62	57
26 to 30	0	0	0	0	11	15
<b>Total</b>	821	721	†130	8	‡771	729

**Table 2ab. Summary Table of Number of Subjects providing plasma samples within each ADNI Study Phase.** Table 2 (above) corresponds to Figures 2a and 2b, detailing the number of subjects who have provided plasma samples at Baseline and at 1 year follow-up within each ADNI study phase (ADNI 1, GO, and 2). Again, “De Novo” indicates that these are subjects who were initially enrolled in an ADNI study phase and followed up within that study phase. ADNI 1 “De Novo”, for example, indicates that 138 of the subjects initially enrolled in ADNI 1 provided between 6 and 10 plasma aliquots at Baseline, and likewise, there were 83 ADNI 1 subjects who provided between 6 and 10 plasma aliquots at the 1 year follow-up within ADNI 1.


† As of 12/2011, a total of 130 out of the 136 subjects enrolled in ADNI GO have provided plasma samples at Baseline. Plasma samples at 1-year follow-up are completed.

‡ As of 1/2014, a total of 771 out of the 802 subjects enrolled in ADNI 2 have provided plasma samples at Baseline. By 1/2015, the final number of plasma samples at 1-year follow-up that have been collected will be known.

[Table of Contents](#)




## Currently Available Plasma Aliquots at Baseline for all ADNI (Graph)



**Figure 2c. Comparison of Available Plasma Aliquots at Baseline for ADNI 1, GO, and 2.** The graph above displays the number of aliquots currently available from subjects who have provided plasma samples at Baseline in ADNI 1, GO, and 2. The volume of each plasma aliquot is 0.5 ml. For example, there are currently between 6 and 10 plasma aliquots available for 138 of the subjects from ADNI 1, compared to 12 subjects from ADNI GO and 48 subjects from ADNI 2.

[Table of Contents](#)

## Currently Available Plasma Aliquots at 1-yr Follow-Up for all ADNI (Graph)



**Figure 2d. Number of Available Plasma Aliquots at 1 Year Follow-Up for ADNI 1, GO, and 2.** The graph above displays the number of aliquots currently available from subjects who have provided plasma samples at 1-yr follow-up in ADNI 1, GO, and 2. The volume of each plasma aliquot is 0.5 ml. For example, there are currently between 6 and 10 plasma aliquots available for 83 of the subjects from ADNI 1, compared to 4 subjects from ADNI GO and 28 subjects from ADNI 2.

[Table of Contents](#)

## Summary Table of Currently Available Plasma aliquots for all ADNI

### Summary Table of Number of Subjects providing plasma samples within each ADNI Study Phase

Frequency of <b>Currently Available</b> Aliquots at BL and Yr 1 Follow-Up (De Novo)						
Number of Aliquots	ADNI 1		ADNI GO		ADNI 2	
	BL	Yr 1	BL	Yr 1	BL	Yr 1
0	0	0	0	0	0	0
1 to 5	42	33	4	0	6	4
6 to 10	138	83	12	4	44	28
11 to 15	444	317	43	1	171	168
16 to 20	194	284	59	3	477	457
21 to 25	3	4	12	0	62	57
26 to 30	0	0	0	0	11	15
<b>Total</b>	821	721	†130	8	‡771	729


**Table 2cd. Summary Table of Number of Subjects providing plasma samples within each ADNI Study Phase.** Table 2 (above) corresponds to Figures 2c and 2d, detailing the number of subjects who have provided plasma samples at Baseline and at 1 year follow-up within each ADNI study phase (ADNI 1, GO, and 2). Again, “De Novo” indicates that these are subjects who were initially enrolled in an ADNI study phase and followed up within that study phase. ADNI 1 “De Novo”, for example, indicates that currently there are between 6 and 10 Baseline plasma aliquots for 138 of the subjects initially enrolled in ADNI 1, and likewise, there are currently between 6 and 10 plasma aliquots for 83 of the ADNI 1 subjects at the 1-year follow-up. Again, this includes the number of aliquots from samples that were initially received thawed and therefore re-drawn at a later date.

† As of 12/2011, a total of 130 out of the 136 subjects enrolled in ADNI GO have provided plasma samples at Baseline. Plasma samples at 1-year follow-up are completed.

‡ As of 1/2014, a total of 771 out of the 802 subjects enrolled in ADNI 2 have provided plasma samples at Baseline. By 1/2015, the final number of plasma samples at 1-year follow-up that have been collected will be known.

[Table of Contents](#)

## Originally Received Plasma Aliquots at Baseline and Follow-Up Visit for ADNI 1



**Figure 3a. Number of Originally Received Plasma Aliquots at Baseline and Follow-Up Visits within ADNI 1.** The graph above displays the frequency of number of plasma aliquots provided by subjects who were initially enrolled in ADNI 1 and followed up within the ADNI 1 study phase. For example, of those enrolled in ADNI 1, we originally received between 6 and 10 plasma aliquots from 138 of the subjects who provided plasma at Baseline, compared to that of 83 subjects at 1-year follow-up, 43 subjects at 2-year follow-up, 34 subjects at 3-year follow-up, and 10 subjects at the 4-year follow-up.

[Table of Contents](#)

## Originally Received Plasma Aliquots at Baseline and Follow-Up Visits for ADNI 1 (Table)


### Summary Table of ADNI Subjects providing plasma samples at Baseline and at Follow-Up Visits within ADNI 1

ADNI 1 <i>Originally Received</i> Longitudinal Samples					
Number of Aliquots	BL	Yr 1	Yr 2	Yr 3	Yr 4
0	0	0	0	0	0
1 to 5	42	33	9	11	2
6 to 10	138	83	43	34	10
11 to 15	444	317	135	99	29
16 to 20	194	284	404	253	57
21 to 25	3	4	31	30	8
26 to 30	0	0	0	0	0
31 to 35	0	0	0	0	0
36 to 40	0	0	0	0	0
41 to 45	0	0	0	0	0
46 to 50	0	0	1	0	0
<b>Total</b>	821	721	623	427	106

**Table 3a. Summary Table of ADNI Subjects providing plasma samples at Baseline and at Follow-Up Visits within ADNI 1.** Table 3 (above) corresponds to Figure 3a, detailing the number of plasma aliquots that were originally received for subjects enrolled in ADNI 1 at Baseline as well as during the follow-up visits within the ADNI 1 study phase. Again, this includes the number of aliquots from samples that were initially received thawed and therefore re-drawn at a later date.

[Table of Contents](#)

## Currently Available Plasma Aliquots at Baseline and Follow-Up Visits for ADNI 1 (Graph)



**Figure 3b. Number of Available Plasma Aliquots at Baseline and Follow-Up Visits within ADNI 1.** The graph above displays the frequency of number of currently available of plasma aliquots provided by subjects who were initially enrolled in ADNI 1 and followed up within the ADNI 1 study phase. For example, of those enrolled in ADNI 1, there are currently between 6 and 10 plasma aliquots available from 138 of the subjects who provided plasma at Baseline, compared to that of 83 subjects at 1-year follow-up, 49 subjects at 2-year follow-up, 40 subjects at 3-year follow-up, and 10 subjects at the 4-year follow-up.

[Table of Contents](#)

## Currently Available Plasma Aliquots at Baseline and Follow-Up Visits for ADNI 1 (Table)


### Summary Table of ADNI Subjects providing plasma samples at Baseline and at Follow-Up Visits within ADNI 1

ADNI 1 <u>Currently Available</u> Longitudinal Samples					
Number of Aliquots	BL	Yr 1	Yr 2	Yr 3	Yr 4
0	0	0	0	0	0
1 to 5	42	33	20	15	3
6 to 10	138	83	49	40	10
11 to 15	444	317	264	157	40
16 to 20	194	284	278	203	51
21 to 25	3	4	11	12	2
26 to 30	0	0	1	0	0
31 to 35	0	0	0	0	0
36 to 40	0	0	0	0	0
41 to 45	0	0	0	0	0
46 to 50	0	0	0	0	0
<b>Total</b>	<b>821</b>	<b>721</b>	<b>623</b>	<b>427</b>	<b>106</b>

**Table 3b. Summary Table of ADNI Subjects providing plasma samples at Baseline and at Follow-Up Visits within ADNI 1.** Table 3b (above) corresponds to Figure 3b, detailing the number of plasma aliquots that currently remain in our repository for subjects enrolled in ADNI 1 at Baseline as well as during the follow-up visits within the ADNI 1 study phase.

[Table of Contents](#)

## Originally Received Plasma Aliquots for ADNI 2 at BL and Follow-Up Visits (Graph)



**Figure 4a. Number of Originally Received Plasma Aliquots at Baseline and Follow-Up Visits in ADNI 2 (including Roll-over Subjects from ADNI 1 and ADNI GO).** The graph above displays the frequency of number of plasma aliquots provided by subjects enrolled in the ADNI 2 study phase at Baseline and at Follow-Up visits. Subjects who provided plasma samples at Baseline in ADNI 2 are those who were initially enrolled in ADNI 2. The follow-up visits here include subjects who rolled over into ADNI 2 from either ADN1 or ADNI GO.

[Table of Contents](#)



## Originally Received Plasma Aliquots for ADNI 2 at BL and Follow-Up Visits (Table)

### Summary Table of Subjects providing Plasma samples at Baseline and at Follow-Up visits in ADNI 2 (including Roll-overs from ADNI 1 and GO)


ADNI 2 <i>Originally Received</i> Longitudinal Samples (including Rollovers from ADNI 1 and GO)										
Number of Aliquots	BL	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9
0	0	0	0	0	0	0	0	0	0	0
1 to 5	6	4	3	2	1	0	1	0	0	0
6 to 10	44	28	17	7	0	6	6	4	6	0
11 to 15	171	168	131	35	10	35	43	47	26	0
16 to 20	477	457	338	119	22	111	140	111	49	1
21 to 25	62	57	38	11	5	14	16	13	10	1
26 to 30	11	15	19	8	0	0	1	1	1	0
<b>Total</b>	771	729	546*	182	38	166	207	176	92	2

**Table 4a. Summary Table of Subjects providing Plasma samples at Baseline and at Follow-Up visits in ADNI 2 (including Roll-over Subjects from ADNI 1 and ADNI GO).** This is a summary table corresponding to Figure 4a, detailing the number of subjects who provided plasma samples at baseline in ADNI 2 (ADNI 2 enrollees only) as well as at follow-up visits (including subjects who rolled over into ADNI 2 from either ADNI 1 or ADNI GO).

**\*Note:** As of 1/2014, a total of 771 out of the 802 subjects enrolled in ADNI 2 have provided plasma samples at Baseline. Plasma samples at 1-year follow-up are expected to be known by 1/2015 and plasma samples at 2-year follow-up are expected to be known by 1/2016.

[Table of Contents](#)

**Currently Available Plasma Aliquots for ADNI 2 at BL and Follow-Up Visits (Graph)**



**Figure 4b. Number of Available Plasma Aliquots at Baseline and Follow-Up Visits in ADNI 2 (including Roll-over Subjects from ADNI 1 and ADNI GO).** The graph above displays the frequency of number of plasma aliquots provided by subjects enrolled in the ADNI 2 study phase at Baseline and at Follow-Up visits. Subjects who provided plasma samples at Baseline in ADNI 2 are those who were initially enrolled in ADNI 2. The follow-up visits here include subjects who rolled over into ADNI 2 from either ADN1 or ADNI GO.

[Table of Contents](#)

## Currently Available Plasma Aliquots for ADNI 2 at BL and Follow-Up Visits (Table)

### Summary Table of Subjects providing Plasma samples at Baseline and at Follow-Up visits in ADNI 2 (including Roll-overs from ADNI 1 and GO)

ADNI 2 <i>Currently Available</i> Longitudinal Samples (including Rollovers from ADNI 1 and GO)										
Number of Aliquots	BL	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9
0	0	0	0	0	0	0	0	0	0	0
1 to 5	6	4	4	2	1	0	1	0	0	0
6 to 10	44	28	17	7	0	6	6	4	6	0
11 to 15	171	168	131	35	10	35	43	47	26	0
16 to 20	477	457	337	119	22	111	139	111	49	1
21 to 25	62	57	38	11	5	14	16	13	10	1
26 to 30	11	15	19	8	0	0	1	1	1	0
<b>Total</b>	771	729	546	182	38	166	206	176	92	2

**Table 4b. Summary Table of Subjects providing Plasma samples at Baseline and at Follow-Up visits in ADNI 2 (including Roll-over Subjects from ADNI 1 and ADNI GO).** This is a summary table corresponding to Figure 4b, detailing the number of subjects who provided plasma samples at baseline in ADNI 2 (ADNI 2 enrollees only) as well as at follow-up visits (including subjects who rolled over into ADNI 2 from either ADNI 1 or ADNI GO).

[Table of Contents](#)

## Summary of CSF, Plasma, Serum, Whole Blood Aliquots shipped out

Study No.	Shipment date	Address	Contact person/Investigator/PI	Project	Specimen type	Shipment description	Data upload to ADNI/LONI
1	12/4/2007	Milla M. Thompson, M.S., Sr. Clinical Study Manager, Cogenics(tm), A Division of Clinical Data®, Comprehensive Pharmacogenomics and Molecular Biology Services™, 100 Perimeter Park Drive, Suite C Morrisville, NC 27560 USA	1. Andy Saykin, PI (2007-2009)  Dietrich Stephan, co-PI Indiana University  2. Steven Potkin, PI (2007-2009) UC Irvine Andrew Saykin, co-PI Indiana University	1. Whole genome analysis of ADNI 1 cohort following DNA extraction (at Cogenics)  2. Genetic association analysis of the ADNI 1 cohort	Whole blood	<b>807 ADNI 1 samples</b> ADNI 1 Screening/Visit 1 ApoE residual samples	Data uploaded on 3/16/2009
2	7/13/2009	Penny Gwynne/ Lucas Restrepo, Center for Innovations in Medicine, Biodesign Institute, Arizona State University, 1001 South McAlister Avenue Tempe, Arizona 85287	Lucas Restrepo, PI UCLA	Immunosignature of Alzheimer's Disease: using a blood plasma test	Plasma	<b>100 ADNI 1 aliquot samples</b> 50 Vst 2/Baseline AD and 50 Vst 2/Baseline NL	study in progress pending funding
3	7/14/2009	John A. McIntyre, Ph.D, FRC Path, D(ABHI), HLA-Vascular Biology Laboratory, St. Francis Hospital, 1500 Albany Street, Suite 1109 Beech Grove, IN 46107	John A. McIntyre, PI St. Francis Hospital	Redox Reactive Autoantibodies in ADNI subjects, RARC/study phase 1	Serum	<b>18 ADNI 1 aliquot samples</b> Vst 2/Baseline: 6 NC, 6 MCI and 6 AD	Data uploaded on 11/29/2009
4	3/1/2010	John A. McIntyre, Ph.D, FRC Path, D(ABHI), HLA-Vascular Biology Laboratory, St. Francis Hospital, 1500 Albany Street, Suite 1109, Beech Grove, IN 46107	John A. McIntyre, PI St. Francis Hospital	Redox Reactive Autoantibodies in ADNI subjects, RARC/study phase 2	Serum	<b>90 ADNI 1 aliquot samples</b> Vst 2/Baseline: 30 NC, 30 MCI and 30 AD	Data uploaded on 07/21/2011

Study No.	Shipment date	Address	Contact person/Investigator/PI	Project	Specimen type	Shipment description	Dataupload to ADNI/LONI
5	5/12/2010	Ashley Garrett, Rules-Based Medicine, Inc., 3300 Duval Rd Austin, TX 78759	<p>1. Plasma Proteomics study, Holly Soares, PI; Pfizer(2010-2011) Pfizer Eve Pickering and Fred Immerman, Statistical analyses, William Potter, Max Kuhn, David Shera, Mats Ferm, Robert A Dean, Adam J Simon, Frank Swenson, Judy Siuciak, June Kaplow, Madhay Thambisetty, Panayiotis Zagouras, Walter Koroshetz, Hong Wan, John Q Trojanowski, Leslie M Shaw, co-Investigators</p> <p>David Lee, Scientific Program Manager</p> <p>Judy Siuciak, Scientific Program Manager The FNHI Biomarkers Consortium Foundation for the National Institutes of Health</p> <p>2. CSF Proteomics study, William Potter, PI; (2011-2013) Eve Pickering and Fred Immerman, Statistical analyses, Mitch Kling</p>	<p>Plasma proteomic study Rules Based Medicine (RBM)*</p> <p>CSF proteomic study RBM</p>	<p>Plasma</p> <p>CSF</p>	<p><b>1065 ADNI 1 aliquot samples</b> Vst 2/Baseline: 394 MCI, 111 AD, 57 NL Visit 4/Year 1: 349 MCI, 98 AD, 56 NL</p> <p><b>317 ADNI 1 aliquot samples</b> 311 + 16 replicates of Vst 2/Baseline CSF from ADNI subjects who had CSF collected at baseline</p>	<p>1. Plasma proteomics RBM study, Nov 19, 2010</p> <p>2. CSF proteomics RBM study, January 3, 2012</p>
6	3/24/2011	Dr Zhang HMC Harborview Medical Center R+T Building, 3009th Ave Room 321 Seattle, WA, 98104	<p>Jing Zhang, PI Harborview Medical Center, University of Washington School of Medicine;</p> <p>Carmen Gingham, Laboratory Manager, Department of Pathology, University of Washington School of Medicine</p>	ADNI RARC/CSF proteomic study	CSF	<b>390 ADNI 1 aliquot samples</b> Vst 2/Baseline: 92 AD, 187 MCI, 111 NC	Data uploaded on 3/11/2013 and 7/12/2013

Study No.	Shipment date	Address	Contact person/Investigator/PI	Project	Specimen type	Shipment description	Data upload to ADNI/LONI
7	8/9/2011	Ashley Garrett, Rules-Based Medicine, Inc., 3300 Duval Rd, Austin, TX 78759	William Potter, PI; Eve Pickering, Mitch Kling, Les Shaw, Fred Immerman, co-investigators  Judy Siuciak, Scientific Program Manager, The FNHI Biomarkers Consortium	CSF proteomic study RBM*	CSF	<b>317 ADNI 1 aliquot samples</b> 311 + 16 replicates of Vst 2/Baseline CSF from ADNI subjects who had CSF collected at baseline	Data uploaded on 01/03/2012
8	9/26/2011	Guoxin Wu, WP26-440, 770 Sumneytown Pike, West Point, PA 19486,	Mary J Savage, PI Dan Holder, co-PI Merck  Judy Siuciak, PhD, Scientific Program Manager The FNHI Biomarkers Consortium	BACE and sAPP in CSF	CSF	<b>402 ADNI 1 aliquot samples</b> Vst 2/Baseline CSF: 382 CSF aliquots + 20 replicates	Data uploaded on 4/24/2012
9	1/17/2012	Elena Marazzo/Julie Lamontagne Caprion Proteomics Inc., 2005 rue Jeanne-Mance, 3rd Floor, Suite 3900 Montreal, Quebec, Canada, H2X 2J6	Lee Honigsberg, Nicholas Lewin-Koh, Angus Nairn, Les Shaw, Dan Spellman, Kristin Wildsmith, co-Pis  Steve Hoffmann, PhD, Scientific Program Manager The Biomarkers Consortium Foundation for the National Institutes of Health	Pilot Study  CSF proteomics project Caprion using mrm mass spectrometry*	CSF	<b>25 ADNI 1 aliquot samples</b> 20 Vst 2/Baseline CSFs: 10 AD, 10 NL and 5 aliquots of a CSF pool	Data uploaded on 4/04/2014 along with Study #12
10	5/9/2012	Dr Geoff Baird University of Washington Baird c/o ASchantz/Montine Lab 300 9th Avenue HMCR&T Bldg RM 703 Seattle, WA 98104	Geoff Baird, PI; Thomas Montine and Elaine Peskind, co-investigators University of Washington	Analyzing the CSF proteome with an oligonucleotide aptamer array	CSF and Plasma	<b>727 ADNI 1 aliquot samples</b> All available Vst 2/Baseline <b>CSF: 372</b> and matching <b>plasma: 355</b>	study in progress pending funding
11	9/12/2012	Dr. Robert Nagele University of Medicine and Dentistry of New Jersey, 2 Medical Center Drive, Rm 313A, Stratford, NJ 08084	Dr. Robert Nagele, PI UMDNJ	Autoantibody biomarkers for detection and diagnosis of Alzheimer's disease	Serum	<b>100 ADNI 1 aliquot samples</b> 50 Vst 2/Baseline MCI and 50 Vst 2/Baseline NL	Data uploaded on 11/1/2012

Study No.	Shipment date	Address	Contact person/Investigator/PI	Project	Specimen type	Shipment description	Data upload to ADNI/LONI
12	week of 9/24/2012	Caprion	Lee Honigsberg, PI Nicholas Lewin-Koh, Angus Nairn, Les Shaw, Dan Spellman, Kristin Wildsmith, co-investigators  Steve Hoffmann, PhD, Scientific Program Manager, The Biomarkers Consortium, Foundation for the National Institutes of Health	CSF proteomic study Caprion using mrm mass spectrometry	CSF	<b>306 ADNI 1 aliquot samples</b> 290 Vst 2/Baseline CSFs 16 CSF replicate aliquots	Data uploaded on 4/04/2014
13	10/28/2013	Anne Fagan Washington University School of Medicine 425 S. Euclid Ave Fagan-Sutphen 10th Floor BCIH St. Louis, MO 63110	Courtney Sutphen Washington University in St. Louis, MO 63110 Lab of Drs. Anne Fagan and David Holtzman	YKL-40 and VILIP-1 in longitudinal CSF sample sets	CSF	<b>612 ADNI 1, 2, GO aliquot samples</b> 597 Baseline & Longitudinal CSFs 15 Replicates	Study in progress
14	05/19/2014	Phenomenome Discoveries Inc. 204-407 Downey Road Saskatoon, Sk Canada	Rima Kaddurah-Daouk, Ph.D. Duke University	Metabolic Pathways and Networks in Alzheimer's Disease	Serum	<b>833 ADNI 1 aliquot samples</b> 813 Baseline SER 20 Replicates	Study in progress
15	05/19/2014	Clinical Neurology Lab House V3, Floor 2, Moindal Hospital Sahlgrenska University Hospital Moindal, Sweden SE-43180	Clinical Neurochemistry Lab Dr. Kaj Blennow	Cerebrospinal fluid levels of neurogranin	CSF	<b>416 ADNI 1 aliquot samples</b> 400 Baseline CSF 16 Replicates	Data uploaded on 8/20/2014
16	07/09/2014	Emory University CND-Neurology 615 Michael Street Atlanta, GA 30322	Allan Levey MD, PhD Emory Univ. School of Med. 101 Woodruff Circle, WMB Suite 6000 Atlanta, GA 30322	DDE**	Plasma	<b>221 ADNI 1 aliquot samples</b> 211 Baseline Plasma 10 Replicates	Data uploaded on 11/12/2014

17	9/23/2014	Clinical Neurology Lab House V3, Floor 2, Moindal Hospital Sahlgrenska University Hospital Moindal, Sweden SE-43180	Clinical Neurochemistry Lab Dr. Kaj Blennow	Tau Plasma	Plasma	<b>595 ADNI 1 aliquot samples</b> 579 Baseline PLA 16 Replicates	Study in Progress
18	TBD	Dr Zhang HMC Harborview Medical Center R+T Building, 300 9th Ave Room 321 Seattle, WA, 98104	Jing Zhang, PI Harborview Medical Center, University of Washington School of Medicine;  Carmen Ginhina, Laboratory Manager, Department of Pathology, University of Washington School of Medicine	Alpha-synuclein Ser <sup>129</sup> Phosphorylated α-syn C3 FH	CSF	<b>372 pristine ADNI 1 Baseline CSF Aliquot Samples</b> transferred from study #10 along with new longitudinal samples matched to BL CSFs	To be shipped

Type of Sample Shipped	Total # Aliquots Shipped
CSF	3157
Plasma	2336
Serum	1041
Whole Blood	807
<b>Total Shipped</b>	<b>7341</b>

\*PPSB Proteomic studies

\*\* DDE, a metabolite of pesticide DDT (dichloro-diphenyl-trichloroethane)


**Table/Figure 5. Summary of CSF, Plasma, Serum, Whole Blood Aliquots shipped out.** The table above is a description of aliquots that were sent out to other investigators in the past 8 years (2007 through 2015). A total of 3157 CSF aliquots, 2336 plasma aliquots, 1041 serum aliquots, and 807 whole blood samples have been shipped out.

**\*\*\*GRAND TOTAL of collected CSF, Plasma, and Serum Aliquots: 295,209**

[Table of Contents](#)



**Summary of Plasma aliquots use for Luminex runs**




Visit	ADNI 1	ADNI GO	ADNI 2	Total
BL	583	0	0	583
M6	16	0	0	16
M12	596	0	0	596
M18	17	0	0	17
M24	437	0	0	437
M36	184	0	0	184
M48	8	0	0	8
M60	0	0	0	0
M72	0	0	0	0
M84	0	0	0	0
Total	1841	0	0	1841

**Figure 6. Graph of Summary of Plasma Aliquots used for Luminex runs**

**Table 6. Summary of Plasma aliquots used for Luminex runs.**

Both Figure 6 and Table 6 provide a description of the plasma aliquots that were used for luminex runs. In total, 1841 plasma aliquots from ADNI 1 have been used as of *Jan.5<sup>th</sup>, 2015*. Plasma aliquots from ADNI GO and ADNI 2 have not yet been used for luminex.

## Subjects Providing Plasma at Baseline in each ADNI DOD (Graph)



**Figure 7. Percentage of subjects who provided Plasma at Baseline in ADNI DOD.** The figure above compares the percentage of those enrolled in ADNI DOD who provided CSFs at Baseline. As of *January 5th, 2015* (cut-off date used for this report), approximately 98.29% of ADNI DOD subjects provided plasma samples at baseline.

[Table of Contents](#)

## Subjects Providing Plasma at Baseline and Year 1 Follow-Up in each ADNI DOD (Table)

### Summary Table of Percentage of subjects providing Plasma samples within ADNI DOD at Baseline and at 1 year Follow-Up


ADNI Group	Baseline			Year 1 Follow-Up	
	Number of Subjects enrolled as of <u>1/5/2015</u>	Number who provided Plasma as of <u>1/5/2015</u>	% who provided Plasma	Number who provided Plasma as of <u>1/5/2015</u>	% who provided Plasma
ADNI DOD	117	†115	98.29%	25	21.37%

**Table 7. Summary Table of Percentage of subjects providing Plasma samples within ADNI DOD at Baseline and at 1 year Follow-Up.** This is a summary table for Figure 7, detailing the number and percent of subjects providing plasma samples within ADNI DOD, as well as the number of those who provided plasma samples at 1 year follow-up as of 1/5/2015.

† As of 11/2014, a total of 115 out of the 117 subjects initially enrolled in ADNI DOD have provided plasma samples at Baseline. By 11/2015, the final number of plasma samples at 1-year follow-up that have been collected will be known.

[Table of Contents](#)

## Originally Received Plasma Aliquots for ADNI DOD at BL and Follow-Up Visits (Graph)



**Figure 8a. Number of Originally Received Plasma Aliquots for ADNI DOD at Baseline and Yr 1.** The graph above displays the number of subjects who have provided Plasma samples during the ADNI DOD at baseline and at Year 1 follow-up visit. We originally received between 16 and 20 plasma aliquots per subject from 92 individuals at baseline and 15 from Year 1 follow-up visit.

[Table of Contents](#)

## Originally Received Plasma Aliquots for ADNI DOD at BL and Year 1 Follow-Up (Table)

### Summary Table of Originally Received Plasma Aliquots from subjects at Baseline and at Yr 1 Follow-Up visit in ADNI DOD


ADNI DOD - <u>Originally Received</u>		
Number of Plasma Aliquots	BL	Yr 1 Follow-Up
0	0	0
1 to 5	0	0
6 to 10	2	0
11 to 15	16	10
16 to 20	92	15
21 to 25	4	0
26 to 30	1	0
31 to 35	0	0
36 to 40	0	0
41 to 45	0	0
46 to 50	0	0
<b>Total</b>	†115	25

**Table 8b. Summary Table of Originally Received Plasma Aliquots from subjects at Baseline and at Yr 1 Follow-Up visits in ADNI DOD.** This is a summary table corresponding to Figure 8a, detailing the number of subjects who provided plasma samples at baseline in ADNI DOD as well as at year 1 follow-up visit.

† As of 11/2014, a total of 115 out of the 117 subjects initially enrolled in ADNI DOD have provided plasma samples at Baseline. By 11/2015, the final number of plasma samples at 1-year follow-up that have been collected will be known.

[Table of Contents](#)

## Currently Available Plasma Aliquots for ADNI DOD at BL and Year 1 Follow-Up (Graph)



**Figure 9a. Number of Currently Available Plasma Aliquots for ADNI DOD at Baseline and Yr 1 Follow-Up Visit.** The graph above displays the number of subjects who have provided plasma samples during the ADNI DOD at baseline and at Year 1 follow-up visit. We currently have between 16 and 20 plasma aliquots per subject from 77 individuals at baseline and 15 from Year 1 follow-up visit.

[Table of Contents](#)

## Currently Available Plasma Aliquots for ADNI DOD at BL and Year 1 Follow-Up (Table)

### Summary Table of Subjects providing Plasma samples at Baseline and at Yr 1 Follow-Up visit in ADNI DOD

ADNI DOD - <u>Currently Available</u>		
Number of Plasma Aliquots	BL	Yr 1 Follow-Up
0	0	0
1 to 5	0	0
6 to 10	2	0
11 to 15	31	10
16 to 20	77	15
21 to 25	4	0
26 to 30	1	0
31 to 35	0	0
36 to 40	0	0
41 to 45	0	0
46 to 50	0	0
<b>Total</b>	†115	25

**Table 9b. Summary Table of Subjects providing Plasma samples at Baseline and at Yr 1 Follow-Up visit in ADNI DOD.** This is a summary table corresponding to Figure 9b, detailing the number of subjects who provided plasma samples at baseline in ADNI DOD as well as at Year 1 follow-up visits.

† As of 11/2014, a total of 115 out of the 117 subjects initially enrolled in ADNI DOD have provided plasma samples at Baseline. By 11/2015, the final number of plasma samples at 1-year follow-up that have been collected will be known.

[Table of Contents](#)